Abstract
Patient-controlled analgesia (PCA) with intravenous morphine is commonly used to control moderate-to-severe postoperative pain. The US FDA recently approved a transdermal system for patient-controlled iontophoretic delivery of fentanyl as an alternative treatment. Aside from the route of administration, other differences between these systems may result in differing adverse-effect profiles. This review compares the clinical utility of these two modalities. MEDLINE, Cinahl and Google Scholar searches for clinical trials (1982 through to July 2007) were performed. Search terms included transdermal analgesia, iontophoresis, patient-controlled analgesia, IONSYS™ and E-TRANS®. All trials comparing intravenous morphine PCA with the transdermal iontophoretic fentanyl system (fentanyl ITS) were included. CONSORT diagrams and adverse-event frequencies were available in all cases. Results demonstrated that fentanyl ITS and intravenous PCA morphine are equally effective analgesics for the management of acute postoperative pain. Fentanyl ITS is associated with fewer treatment failures due to adverse events (p = 0.046), less pruritus (p = 0.001) and less somnolence (p = 0.055). Intravenous PCA morphine is associated with fewer treatment failures due to inadequate analgesia (p = 0.001). It was concluded that fentanyl ITS is an equally safe and effective alternative to intravenous PCA morphine. Advantages favoring fentanyl ITS include convenience and ease-of-care.
Financial & competing interests disclosure
The author has previously received research support and received an honorarium for consulting in 2005 from Ortho-McNeil.
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.